Date: 2014-12-01
Type of information: Presentation of results at a congress
phase: 2
Announcement: presentation of results at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014.
Company: Cell Therapeutics, now CTI Biopharma (USA - WA) Cancer Research UK (UK) Cardiff University (UK)
Product: pacritinib
Action
mechanism: tyrosine kinase inhibitor. Pacritinib is an oral JAK2/FLT3 inhibitor that has demonstrated encouraging activity in preclinical models of AML with mutated FLT3 gene, including additional FLT3 mutations that confer resistance to other targeted FLT3 agents.
Disease: relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene
Therapeutic area: Cancer - Oncology
Country: UK
Trial
details: The trial is being conducted by the AML Working Group of the National Cancer Research Institute Haematological Oncology Study Group in Acute Myeloid Leukemia (AML) and high risk Myelodysplastic Syndrome (MDS) under the sponsorship of Cardiff University and supported by Cancer Research UK. The trial management group is lead by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University.
This Phase 2 trial is part of a larger ongoing study in AML, referred to as the AML17 trial, which includes multiple arms evaluating first line regimens for AML. Patients with the FLT3 mutation, who are enrolled in this study and relapse following standard therapy, will be offered therapy with pacritinib. Approximately 80 patients at sites in England and Wales will be enrolled and, if an encouraging response rate is observed, a pacritinib arm may be adopted in the first line therapy study.
Latest
news:
